Efficacy and safety of infliximab biosimilar Inflectra
| Autor: | Milou C, Schimmelpennink, Adriane D M, Vorselaars, Frouke T, van Beek, Heleen A, Crommelin, Vera H M, Deneer, Ruth G M, Keijsers, Marcel, Veltkamp |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Health Status Vital Capacity Receptors Interleukin-2 Middle Aged Peptidyl-Dipeptidase A Infections Antibodies Neutralizing Severity of Illness Index Infliximab Respiratory Function Tests Cohort Studies Hospitalization Treatment Outcome Sarcoidosis Pulmonary Fluorodeoxyglucose F18 Antirheumatic Agents Positron-Emission Tomography Quality of Life Humans Female Radiopharmaceuticals Biosimilar Pharmaceuticals Retrospective Studies |
| Zdroj: | Respiratory medicine. |
| ISSN: | 1532-3064 |
| Popis: | Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in severe sarcoidosis. The originator product of Infliximab, RemicadeIn this retrospective cohort study, 29 patients treated with the infliximab biosimilar InflectraIn patients with pulmonary sarcoidosis as main treatment indication (n = 15) the predicted FVC improved with 8.1%, p 0.05. Furthermore, in the whole group HRQoL improved significantly (p 0.001), whereas SUVmax and sIL-2R significantly reduced (p 0.001 and p = 0.001 respectively). Hospitalisation due to infections occurred in four patients. None of the patients discontinued InflectraInfliximab biosimilar Inflectra |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect